Should HBV DNA NAT replace HBsAg and/or anti-HBc screening of blood donors?
- 23 January 2004
- journal article
- review article
- Published by Elsevier in Transfusion Clinique et Biologique
- Vol. 11 (1) , 26-32
- https://doi.org/10.1016/j.tracli.2003.12.003
Abstract
No abstract availableKeywords
This publication has 18 references indexed in Scilit:
- The cost‐effectiveness of NAT for HIV, HCV, and HBV in whole‐blood donationsTransfusion, 2003
- Comparative sensitivity of HBV NATs and HBsAg assays for detection of acute HBV infectionTransfusion, 2003
- Superiority of minipool nucleic acid amplification technology for hepatitis B virus over chemiluminescence immunoassay for hepatitis B surface antigen screeningVox Sanguinis, 2003
- NAT for HBV and anti‐HBc testing increase blood safetyTransfusion, 2002
- HBV: amplified and back in the blood safety spotlightTransfusion, 2001
- Comparison of the sensitivity of NAT using pooled donor samples for HBV and that of a serologic HBsAg assayTransfusion, 2001
- Analysis of HBV infection after blood transfusion in Japan through investigation of a comprehensive donor specimen repositoryTransfusion, 2001
- Persistent Hepatitis B Virus Infection in Subjects Without Hepatitis B Surface Antigen: Clinically Significant or Purely “Occult”?Hepatology, 2001
- The hepatitis B virus persists for decades after patients' recovery from acute viral hepatitis despite active maintenance of a cytotoxic T–lymphocyte responseNature Medicine, 1996
- Type B Hepatitis after Transfusion with Blood Containing Antibody to Hepatitis B Core AntigenNew England Journal of Medicine, 1978